# ABBV — AbbVie · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ABBV  
**Sources:** 23  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-abbv-abbvie-catalysts-narrative-risks-5794

---

## Quick Snapshot (as of 2026-10-03)

AbbVie (NYSE:ABBV) is a Chicago-based biopharmaceutical company. In early October 2026 the stock trades in the low-$260s — Yahoo Finance shows a previous close of $259.93 with a day range of $257.87–$264.06, and another quote places it near $263.61, up ~18% year-to-date — with a market cap of roughly $464B and a 52-week range of $190.75–$269.39 [[20]](https://finance.yahoo.com/quote/ABBV/). A 1-year analyst price target sits around $278.86 [[20]](https://finance.yahoo.com/quote/ABBV/). The company pays a forward dividend on the order of $6.83–$6.92 per share (about a 2.66% yield) [[2]](https://247wallst.com/investing/2026/09/30/bofa-boosts-abbvie-and-jj-price-targets-on-growth-and-pipeline-strength/)[[20]](https://finance.yahoo.com/quote/ABBV/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-abbv-abbvie-catalysts-narrative-risks-5794 (free to sign up)._
